Hyundai Pharm - Asset Resilience Ratio
Hyundai Pharm (004310) has an Asset Resilience Ratio of 0.16% as of May 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 004310 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Hyundai Pharm's Asset Resilience Ratio has changed over time. See 004310 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hyundai Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 004310 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩267.91 Million | 0.16% |
| Total Liquid Assets | ₩267.91 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Hyundai Pharm maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hyundai Pharm Industry Peers by Asset Resilience Ratio
Compare Hyundai Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Hyundai Pharm (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Hyundai Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 0.17% | ₩271.73 Million ≈ $184.15K |
₩156.40 Billion ≈ $105.99 Million |
-1.40pp |
| 2023-11-30 | 1.58% | ₩2.44 Billion ≈ $1.65 Million |
₩154.63 Billion ≈ $104.79 Million |
-0.78pp |
| 2022-11-30 | 2.36% | ₩4.27 Billion ≈ $2.89 Million |
₩181.16 Billion ≈ $122.77 Million |
+2.00pp |
| 2021-11-30 | 0.35% | ₩580.10 Million ≈ $393.13K |
₩163.86 Billion ≈ $111.04 Million |
-4.20pp |
| 2020-11-30 | 4.55% | ₩7.17 Billion ≈ $4.86 Million |
₩157.50 Billion ≈ $106.74 Million |
+4.17pp |
| 2013-11-30 | 0.38% | ₩543.24 Million ≈ $368.14K |
₩143.40 Billion ≈ $97.18 Million |
+0.15pp |
| 2012-11-30 | 0.23% | ₩343.24 Million ≈ $232.61K |
₩149.90 Billion ≈ $101.59 Million |
+0.01pp |
| 2011-11-30 | 0.22% | ₩343.24 Million ≈ $232.61K |
₩156.95 Billion ≈ $106.36 Million |
-- |
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more